These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

869 related articles for article (PubMed ID: 17303969)

  • 41. Non-aspirin NSAIDs, cyclooxygenase-2 inhibitors and risk for cardiovascular events-stroke, acute myocardial infarction, and death from coronary heart disease.
    Roumie CL; Choma NN; Kaltenbach L; Mitchel EF; Arbogast PG; Griffin MR
    Pharmacoepidemiol Drug Saf; 2009 Nov; 18(11):1053-63. PubMed ID: 19637402
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Channelling of COX-2 inhibitors to patients at higher gastrointestinal risk but not at lower cardiovascular risk: the Cox2 inhibitors and tNSAIDs description of users (CADEUS) study.
    Depont F; Fourrier A; Merlière Y; Droz C; Amouretti M; Bégaud B; Bénichou J; Moride Y; Velo GP; Sturkenboom M; Blin P; Moore N;
    Pharmacoepidemiol Drug Saf; 2007 Aug; 16(8):891-900. PubMed ID: 17351983
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tolerance of nonsteroidal anti-inflammatory drug-sensitive patients to the highly specific cyclooxygenase 2 inhibitors rofecoxib and valdecoxib.
    Sánchez-Borges M; Caballero-Fonseca F; Capriles-Hulett A
    Ann Allergy Asthma Immunol; 2005 Jan; 94(1):34-8. PubMed ID: 15702813
    [TBL] [Abstract][Full Text] [Related]  

  • 44. More pronounced inhibition of cyclooxygenase 2, increase in blood pressure, and reduction of heart rate by treatment with diclofenac compared with celecoxib and rofecoxib.
    Hinz B; Dormann H; Brune K
    Arthritis Rheum; 2006 Jan; 54(1):282-91. PubMed ID: 16385545
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hospitalization for gastrointestinal bleeding associated with non-steroidal anti-inflammatory drugs among elderly patients using low-dose aspirin: a retrospective cohort study.
    Rahme E; Bardou M; Dasgupta K; Toubouti Y; Ghosn J; Barkun AN
    Rheumatology (Oxford); 2007 Feb; 46(2):265-72. PubMed ID: 16844699
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cardiovascular issues of COX-2 inhibitors and NSAIDs.
    Wong M; Chowienczyk P; Kirkham B
    Aust Fam Physician; 2005 Nov; 34(11):945-8. PubMed ID: 16299629
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib.
    Bäck M; Yin L; Ingelsson E
    Eur Heart J; 2012 Aug; 33(15):1928-33. PubMed ID: 22108833
    [TBL] [Abstract][Full Text] [Related]  

  • 48. COX-2 selective inhibitors and heart health.
    Simon LS; White WB
    Postgrad Med; 2005 Jan; 117(1 Suppl):7-20. PubMed ID: 19667717
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Risk of congestive heart failure with nonsteroidal antiinflammatory drugs and selective Cyclooxygenase 2 inhibitors: a class effect?
    Hudson M; Rahme E; Richard H; Pilote L
    Arthritis Rheum; 2007 Apr; 57(3):516-23. PubMed ID: 17394181
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cyclooxygenase-2 enzyme inhibitors: place in therapy.
    Noble SL; King DS; Olutade JI
    Am Fam Physician; 2000 Jun; 61(12):3669-76. PubMed ID: 10892637
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Tubulointerstitial nephritis associated with treatment with selective Cox-2 inhibitors, celecoxib and rofecoxib].
    Ortiz M; Mon C; Fernández MJ; Sánchez R; Mampaso F; Alvarez Ude F
    Nefrologia; 2005; 25(1):39-43. PubMed ID: 15789535
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Persistence with COX-2 inhibitors in managed care: an analysis of claims data.
    Harley C; Wagner S
    Manag Care Interface; 2003 Oct; 16(10):38-45. PubMed ID: 14606259
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction.
    Andersohn F; Suissa S; Garbe E
    Circulation; 2006 Apr; 113(16):1950-7. PubMed ID: 16618816
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study.
    Mamdani M; Juurlink DN; Lee DS; Rochon PA; Kopp A; Naglie G; Austin PC; Laupacis A; Stukel TA
    Lancet; 2004 May; 363(9423):1751-6. PubMed ID: 15172772
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease.
    Mahadevan U; Loftus EV; Tremaine WJ; Sandborn WJ
    Am J Gastroenterol; 2002 Apr; 97(4):910-4. PubMed ID: 12008668
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis.
    Becker MC; Wang TH; Wisniewski L; Wolski K; Libby P; Lüscher TF; Borer JS; Mascette AM; Husni ME; Solomon DH; Graham DY; Yeomans ND; Krum H; Ruschitzka F; Lincoff AM; Nissen SE;
    Am Heart J; 2009 Apr; 157(4):606-12. PubMed ID: 19332185
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Postmarketing surveillance of serious adverse events associated with the use of rofecoxib from 1999-2002.
    Bottone FG; Barry WT
    Curr Med Res Opin; 2009 Jun; 25(6):1535-50. PubMed ID: 19453292
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cardiovascular events associated with long-term use of celecoxib, rofecoxib and meloxicam in Taiwan: an observational study.
    Huang WF; Hsiao FY; Tsai YW; Wen YW; Shih YT
    Drug Saf; 2006; 29(3):261-72. PubMed ID: 16524325
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cyclooxygenase-2 specific inhibitors and upper gastrointestinal tolerability in patients with osteoarthritis receiving concomitant low dose aspirin: pooled analysis of 2 trials.
    Goldstein JL; Bello AE; Spalding W; Suh S; Fort JG
    J Rheumatol; 2005 Jan; 32(1):111-7. PubMed ID: 15630735
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction.
    Kimmel SE; Berlin JA; Reilly M; Jaskowiak J; Kishel L; Chittams J; Strom BL
    Ann Intern Med; 2005 Feb; 142(3):157-64. PubMed ID: 15684203
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.